--- title: "Compass Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295100205.md" datetime: "2026-08-06T11:32:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295100205.md) - [en](https://longbridge.com/en/news/295100205.md) - [zh-HK](https://longbridge.com/zh-HK/news/295100205.md) generator: "portal-rs" --- # Compass Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -0.13. EBIT: As of FY2026 Q2, the actual value is USD -25.15 M. ### Financial Performance #### Net Loss Compass Therapeutics, Inc. reported a net loss of - $25.2 million for the quarter ended June 30, 2026, compared to - $19.9 million for the same period in 2025. For the six months ended June 30, 2026, the net loss was - $43.5 million, compared to - $36.5 million for the same period in 2025. The net loss per common share was - $0.13 for Q2 2026, an improvement from - $0.14 per common share in Q2 2025. For the six months ended June 30, 2026, the net loss per common share was - $0.23, an improvement from - $0.26 per common share in the prior year period. The loss from operations for Q2 2026 was - $26.979 million, compared to - $21.066 million in Q2 2025. For the six months ended June 30, 2026, the loss from operations was - $47.278 million, compared to - $39.032 million in the prior year period. #### Research and Development (R&D) Expenses R&D expenses increased by $3.2 million (19%) to $19.6 million for the quarter ended June 30, 2026, from $16.4 million in the same period of 2025, primarily due to a $2.6 million increase related to tovecimig. For the six months ended June 30, 2026, R&D expenses rose by $3.5 million (12%) to $33.0 million, from $29.5 million in 2025, driven mainly by a $2.5 million increase in stock compensation expense and a $1.3 million increase in manufacturing expense. #### General and Administrative (G&A) Expenses G&A expenses for the quarter ended June 30, 2026, were $7.4 million, an increase of $2.7 million (59%) from $4.7 million in Q2 2025, primarily due to $1.4 million in pre-commercialization expenses and $0.8 million in higher stock compensation expense. For the six months ended June 30, 2026, G&A expenses increased by $4.7 million (50%) to $14.3 million, from $9.6 million in 2025, primarily due to a $3.1 million increase in pre-commercialization expenses and a $2.1 million increase in stock compensation expense. #### Interest Income Interest income for Q2 2026 was $1.825 million, up from $1.185 million in Q2 2025. For the six months ended June 30, 2026, interest income was $3.807 million, compared to $2.518 million in the prior year period. #### Cash Position As of June 30, 2026, Compass Therapeutics, Inc. held $180 million in cash and marketable securities, a decrease of $29 million from $209 million as of December 31, 2025. #### Cash Flow During the first six months of 2026, - $32 million net cash was used in operating activities, partially offset by $3 million cash provided by financing activities. ### Operational Metrics #### Tovecimig (DLL4 x VEGF-A bispecific antibody) In April 2026, Compass Therapeutics, Inc. announced positive data from its Phase 2⁄3 study of tovecimig, with the overall response rate (ORR) improving to 18.0% (20⁄111 patients) in the tovecimig combination arm, showing a p-value of 0.0228 compared to paclitaxel alone (ORR of 5.3%). Investigator-sponsored trials (ISTs) for tovecimig are ongoing in indications such as biliary tract cancer (BTC), colorectal cancer, and glioblastoma. #### CTX-8371 (PD-1 x PD-L1 bispecific antibody) Cohort expansions for CTX-8371 are actively enrolling patients with triple-negative breast cancer (n=28), non-small cell lung cancer (n=28), and Hodgkin lymphoma (n=12) in the post-checkpoint inhibitor setting. #### CTX-10726 (PD-1 x VEGF-A bispecific antibody) The first patients have been dosed in the actively enrolling Phase 1 study for CTX-10726, a tetravalent PD-1 x VEGF-A bispecific antibody engineered by the company that exhibits more potent PD-1 blockade compared to other drugs in its class. The multi-center study will include four doses (0.3, 1.0, 3.0, and 10.0 mg/kg) in a 3+3 dose-escalation design, enrolling patients with specific solid tumor indications where standard therapies have failed. #### CTX-471 (CD137 or 4-1BB agonist antibody) The Phase 2 trial of CTX-471 in patients with tumors expressing NCAM (CD56) is scheduled to be initiated in Q3 2026. ### Outlook / Guidance Compass Therapeutics, Inc. expects feedback from the FDA in Q3 2026 regarding tovecimig Phase 2⁄3 data, ahead of a potential Biologics License Application (BLA) filing later in 2026. Initial clinical data for CTX-10726 and additional data from CTX-8371 cohort expansions are anticipated in Q4 2026. The company’s cash and marketable securities of $180 million as of Q2 2026 are projected to fund operations into 2028. ### Related Stocks - [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md) ## Related News & Research - [Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 | CMPX Stock News](https://longbridge.com/en/news/293052670.md) - [Compass Showcases Promising Tovecimig Data, Eyes Commercialization](https://longbridge.com/en/news/291469511.md) - [Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win](https://longbridge.com/en/news/289061027.md) - [Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged](https://longbridge.com/en/news/284246322.md) - [Compass Therapeutics To Present Phase 1 Data Results Of CTX-8371 At ASCO 2026](https://longbridge.com/en/news/287599766.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**